Prostate Neoantigens And Their Uses
AssigneeJanssen Biotech, Inc.
InventorsJason Lee DeHart, Vipul Bhargava, Manuel Alejandro Sepulveda
Life of this patent
Estimating the term…
Abstract
Disclosed herein are self-replicating RNA molecules encoding prostate neoantigens, vaccines, and methods of treating and preventing prostate cancer.
Claims44
A self-replicating RNA molecule comprising an RNA encoding a polypeptide of SEQ ID NO:
- 1001, 1003, or a combination thereof.
(canceled)
6-7. (canceled)
10-24. (canceled)
28-34. (canceled)
A polynucleotide encoding one or more polypeptides selected from the group consisting of SEQ ID NOs:
- 1001, 1003, 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23, 177, and fragments thereof.
40-44. (canceled)
47-51. (canceled)
The method of claim 51, wherein the additional cancer therapeutic agent is a CTLA-4 antibody, a CTLA4 ligand, a PD-1 axis inhibitor, a PD-L1 axis inhibitor, a TLR agonist, a CD40 agonist, an OX40 agonist, hydroxyurea, ruxolitinib, fedratinib, a 41BB agonist, aa CD28 agonist, a STING antagonist, a RIG-1 antagonist, TCR-T therapy, CAR-T therapy, FLT3 ligand, aluminum sulfate, BTK inhibitor, CD38 antibody, CDK inhibitor, CD33 antibody, CD37 antibody, CD25 antibody, GM-CSF inhibitor, IL-2, IL-15, IL-7, CD3 redirection molecules, pomalimib, IFNγ, IFNα, TNFα, VEGF antibody, CD70 antibody, CD27 antibody, BCMA antibody or GPRC5D antibody, or any combination thereof.
The method of claim 51, wherein the checkpoint inhibitor is ipilimumab, cetrelimab, pembrolizumab, nivolumab, cemiplimab, toripalimab, camrelizumab, tislelizumab, dostralimab, spartalizumab, prolgolimab, balstilimab, budigalimab, sasanlimab, avelumab, atezolizumab, durvalumab, envafolimab, or iodapolimab, or any combination thereof.
A method of treating or preventing a prostate cancer in a subject, comprising administering to the subject
- a. a first vaccine comprising a polynucleotide or RNA encoding one or more polypeptides selected from the group consisting of SEQ ID NOs:
- 1001, 1003, 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23, 177;
- and
- b. a second vaccine comprising a polynucleotide or RNA encoding one or more polypeptides selected from the group consisting of SEQ ID NOs:
- 1001, 1003, 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23, 177.
57-60. (canceled)
64-66. (canceled)
68-70. (canceled)
77-86. (canceled)
89-91. (canceled)
Dependencies are inferred from the claim text.